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Objective  To investigate the effect of enhanced external counterpulsation (EECP) on plasma nitric oxide (NO), 
Endothelin 1 (ET1), high sensitive C-reactive protein (HSCRP) and quality of life (QoL) in patients with coronary 
artery disease (CAD).
Methods  We conducted a pilot randomized clinical trial in order to evaluate plasma NO, ET1, HSCRP and QoL 
before and after twenty sessions of EECP (group A) and cardiac rehabilitation (CR, group B) in 42 patients with 
CAD (21 in each group).
Results  Forty-two patients (33 male and 9 female) were included in the study. The mean age was 58.2±10 years. 
The mean HSCRP was 1.52±0.7 in the EECP group and it was reduced to 1.27±0.4 after intervention. The reduction 
in HSCRP was not statistically significant in EECP and CR groups with p=0.33 and p=0.27, respectively. There was 
not significant improvement of NO, ET1, and QoL in the EECP and CR groups shortly after therapy (p>0.05).
Conclusion  Although the short-term EECP treatment in CAD patients improved HSCRP, NO, ET1, and QoL 
compared with the baseline those improvements are not statistically significant. Further studies are necessary 
with large study groups and more sessions.
Keywords  Enhanced external counter pulsation (EECP), Coronary artery disease, Nitric oxide, Endothelins, High-
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INTRODUCTION
Coronary artery disease (CAD) is a leading cause of 
death and disability worldwide. An estimated 17.6 mil-
lion patients in the United States suffer from symptom-
atic CAD and despite optimal medical therapy, such as 
medications, percutaneous coronary intervention, and 
cardiac bypass surgery, there are an estimated up to 
900,000 patients who suffer from disabling angina [1,2].
Despite these advances in surgical and interventional 
cardiology, up to a third of the patients with symptomatic 
CAD are not suitable for or cannot be fully revascularized 
[3].
Enhanced external counterpulsation (EECP) is a non-
pharmacologic therapy for outpatients with angina pec-
toris and chronic heart failure (CHF). It is based on the 
principle of diastolic augmentation to increase the coro-
nary flow while simultaneously decreasing the systolic 
afterload. During diastole, cuffs inflate sequentially from 
the calves proximally to raise the diastolic aortic pressure 
and theoretically increase the coronary perfusion pres-
sure. At the same time, an increased venous return would 
result in an increased cardiac output by Frank-Starling 
mechanism. Then, the cuffs are rapidly decompressed 
at the onset of systole creating a negative pressure that 
decreases the cardiac afterload. EECP is a low risk proce-
dure and approved by the US Food and Drug Administra-
tion for refractory angina and CHF [4].
Atherothrombosis is recognized as a dynamic chronic 
inflammatory process of the vessel wall in which phases 
of inflammatory and thrombotic activity underlie the 
clinical presentation of acute coronary syndromes (ACS). 
Inflammatory markers, such as high-sensitivity C-reac-
tive protein (HSCRP) provide an alternative method for 
the global assessment of cardiovascular risk. Studies have 
shown that plasma levels of HSCRP are a strong inde-
pendent risk predictor of future vascular events among 
individuals with and without known cardiovascular dis-
ease, including those patients who have been recently 
discharged from an ACS. Elevated levels of HSCRP have 
been positively correlated with most cardiovascular risk 
factors and have a strong association with adiposity and 
to a lesser extent to physical inactivity [5].
The endothelial dysfunction has been implicated as a 
major event in the pathogenesis of atherosclerosis. The 
plasma endothelin in CAD patients is higher whereas the 
nitric oxide (NO) level is significantly lower than in nor-
mal people. Endothelin and NO may be used for the risk 
assessment especially in premature CAD and in individu-
als where traditional risk factors are not present [6].
Nevertheless, the impact of EECP treatment on HSCRP, 
Endothelin 1 (ET1), and NO in cardiac patients has not 
been well documented yet. The objective of this study 
was to investigative assess the role of EECP on these bio-
markers of endothelial dysfunction and inflammation in 
CAD patients.
MATERIALS AND METHODS
Study design and participants
This pilot study was designed as a randomized con-
trolled trial. Between April 2012 and March 2013, 42 con-
secutive patients with CAD were assessed for their suit-
ability for inclusion in this study. Patients were referred 
to the physical medicine and rehabilitation clinic (cardiac 
rehabilitation center) of Madani Hospital. The assessor 
and the data analyzer were blinded, but the rehabilitation 
team conducting the interventions could not be blinded. 
The same assessor who was blinded to the group alloca-
tion made all of the measurements for each participant 
before the randomization and at the end of study.
Inclusion criteria were as follows: at least 30 years of 
age; angina pectoris of Canadian Cardiovascular Soci-
ety (CCS) class I to IV despite the appropriate medical 
therapy; CAD diagnosis based on angiography or elec-
trocardiogram or exercise test or cardiac perfusion scan; 
post-myocardial infarction (MI) with following angio-
plasty; and ejection fraction of at least 30%. Exclusion 
criteria were as follows: having unstable angina or acute 
myocardial infarction or decompensated CHF in the pre-
ceding last  month; blood pressure greater than 180/110 
mmHg; severe symptomatic peripheral vascular disease; 
pacemaker; having arrhythmias interfering with EECP 
function; active thrombophlebitis in lower limbs; bleed-
ing diathesis and an international normalized ratio (INR) 
higher than 5; aortic aneurysm with surgery indication; 
pregnancy; severe valvular heart disease; history of ni-
troglycerin medications, such as nitrocantin in the last 
2 weeks; history or symptoms of rheumatologic disease 
and any symptoms of infectious disease such as fever.
After a detailed explanation of the study protocol, a 
written informed consent was obtained from each eli-
gible participant. The study was approved by the local 
research ethics committee and all procedures were con-
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ducted in accordance with the Declaration of Helsinki.
Patients were sequentially allocated into two paral-
lel groups (A and B) with 21 participants in each group. 
Group A underwent EECP for 20 sessions (3 times per 
week). Each EECP session included one hour of EECP 
with Electrocardiogram monitoring. Group B had 20 ses-
sions (3 times per week) of classic cardiac rehabilitation 
exercise protocol consisting of approximately 10 minutes 
of warm-up and light exercise (stretching) followed by 
20 minutes of aerobic exercise including walking (tread-
mill) and bicycling and finally 5 to 10 minutes cool down 
period (stretching). The exercise intensity was individu-
ally prescribed so that the patient heart rates of each 
patient reached to approximately 60% to 80% (gradually 
increased) of the maximum heart rate calculated after 
exercise stress test. Before entering the program, patients 
underwent an exercise testing and we estimated the exer-
cise capacity. 
Socio-demographic information regarding age, sex, 
education status, employment, body mass index (BMI), 
familial history of CAD and risk factors, such as hyper-
tension, chronic renal failure, and diabetes mellitus were 
collected at the baseline.
All subjects underwent an initial evaluation of main 
outcome measures including quality of life (QoL), CCS 
class, NO, HSCRP, and ET1 levels before and after inter-
vention.
The QoL SF-36 is a widely used questionnaire for mea-
suring a self-reported physical and mental health status. 
This questionnaire consists of 36 items measuring physi-
cal and mental health status in relation to eight health 
concepts: physical functioning, role limitations due to 
physical health, bodily pain, general health perceptions, 
vitality (energy/fatigue), social functioning, role limita-
tions due to emotional health, and general mental health 
(psychological distress/wellbeing). Responses to each of 
the SF-36 items are expressed as a score on a 0–100 scale 
for each of the eight health concepts. Higher scores rep-
resent better self-perceived health [7].
The determination of NO, ET1, and HSCRP was per-
formed with obtaining 5 mL of venous blood without 
adding any heparin. All blood samples were immediately 
centrifuged with 2,000 to 3,000 rounds per minute (rpm) 
at room temperature. The serum was extracted and re-
stored at -70°C until further use. 
High-sensitivity assays for C-reactive protein were per-
formed according to methods described by the manufac-
turer (Dade Behring Inc., Deerfield, IL, USA) [8].
The determination of NO in plasma was indirectly per-
formed by the measurement of the stable decomposition 
product nitrite (NO2), employing the Griess reaction [6]. 
Plasma endothelin was estimated by ELISA using DRG’s 
human ET1 Enzyme Immunemetric Assay kit [6]. 
Statistical analysis
Statistical analysis was performed using the SPSS (ver. 
16.0) statistical software (SPSS Inc., Chicago, IL, USA). 
Descriptive statistics were used, providing the numbers 
and percentages for the categorical variables and the 
means, standard deviations, minimum and maximum 
values for the numeric variables. Independent group 
comparisons were conducted using the Mann-Whitney U 
test when the data were assumed not to be normally dis-
tributed. The Friedman test was used for the repeated-
measures analysis. The statistical significance was de-
fined as a p-value of <0.05 [9].
RESULTS
Our study population was comprised of 42 patients with 
documented CAD, 21 patients in the EECP group and 21 
in the CR exercise group. The EECP group was composed 
of 16 men and 5 women with a mean age of 61.8±9.5 
years, while the CR group was composed of 17 men and 
4 women with a mean age of 64.6±9.4 years. In each of 
EECP and CR groups, one patient at first week was lost to 
follow-up due to personal reasons.
The EECP group and the CR group did not differ in de-
mographic characteristics at baseline (p>0.05) (Table 1).
A familial history of CAD in first-degree relatives was 
positive in 7 cases (35%) of the EECP group and in 3 cases 
(15%) of the CR group, but was statistically not significant 
(p=0.27). Four patients (20%) in the EECP group and 8 
(40%) in the CR group had a history of smoking, but this 
was statistically not significant (p=0.30). None of the pa-
tients were current smokers.
Clinical parameters including the QoL SF-36 question-
naire with eight subscales CCS class as well as labora-
tory findings of NO, HSCRP, and ET1 levels between two 
groups before and after intervention are shown in Tables 
2 and 3.
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EECP and CR effect on clinical parameters and labora­
tory findings of CAD
Although there was an improvement in clinical and 
laboratory parameters in the pre-trial and post-trial com-
parison within both groups, there was not any statistically 
significant improvement over time (Tables 4, 5). 
Comparing the amount of improvement in total QoL 
Table 1. Clinical characteristics of EECP and CR group
EECP CR p-value
Hypertension 8 (38) 8 (38) 1
Diabetes 4 (19) 7 (33) 0.48
Hyperlipidemia 8 (38) 7 (33) 1
Weight (kg) 74.6±7.9 (64–90) 74.5±8.0 (64–93) 0.96
Height (cm) 171.1±8.4 (155–185) 170.6±7.8 (155–183) 0.84
Body mass index (kg/m2) 25.6±2.6 (21.6–31.5) 24.5±2.7 (20.4–32.6) 0.98
Left ventricle ejection fraction (%) 45.2±10.8 (30–65) 44.2±9.3 (30–60) 0.75
Values are presented as the number of patients per group (the percentage within each group) or mean±standard de-
viation (range). There were no significant differences (p>0.05) in baseline characteristics between EECP and CR group. 
EECP, enhanced external counterpulsation; CR, cardiac rehabilitation.
Table 2. Comparison of the EECP and CR group in QoL 








   I 1 (5) 4 (20)
   II 11 (55) 12 (60)
   III 8 (40) 4 (20)
   IV - -
QoL-SF36
   Total score 64.9±3.2 66.0±3.7 0.81
   Subscales
Physical function 71.9±4.5 73.0±20.4 0.87
Physical health 58.5±8.3 62.5±8.0 0.73
Emotional problem 63.1±8.6 64.9±9.8 0.97
Energy 56.6±5.1 61.0±4.1 0.51
Well being 65.8±4.3 65.4±3.0 0.93
Social function 67.5±4.1 76.8±4.1 0.11
Pain 72.1±4.7 65.0±30.5 0.39
General health 63.9±3.5 60.2±4.6 0.76
NO level 7.87±0.99 8.28±6.49 0.81
Endothelin 1 level 7.49±2.81 4.58±5.11 0.34
HSCRP level 1.52±0.7 1.98±0.6 0.62
Values are presented as number (%) or mean±standard 
deviation.
EECP, enhanced external counterpulsation; CR, cardiac 
rehabilitation; QoL, quality of life; CCS, Canadian Car-
diovascular Society; NO, nitric oxide; HSCRP, high sensi-
tive C-reactive protein.
Table 3. Comparison of the EECP and CR group in QoL 
and biochemical markers after the intervention
Variable EECP (n=20) CR (n=20) p-value
CCS angina 0.05
   I 3 (15) 10 (50)
   II 16 (80) 9 (45)
   III 1 (5) 1 (5)
   IV - -
QoL-SF36
   Total score 65.4±3.5 69.8±3.5 0.38
   Subscales - -
Physical function 71.6±4.4 76.7±4.5 0.42
Physical health 58.9±7.9 63.7±8.9 0.66
Emotional problem 64.3±7.5 75.5±34 0.34
Energy 57.8±5.6 61.7±4.2 0.58
Well being 68.4±4.2 65±3.6 0.54
Social function 66.2±3.9 77.7±4.4 0.06
Pain 73.8±5 71±6.4 0.73
General health 61.9±3.3 66.4±4.1 0.65
NO level 8.21±1.27 8.31±6.26 0.78
Endothelin 1 level 5.22±0.6 4.34±3.63 0.88
HSCRP level 1.27±0.4 1.75±0.6 0.36
Values are presented as number (%) or mean±standard 
deviation.
EECP, enhanced external counterpulsation; CR, cardiac 
rehabilitation; QoL, quality of life; CCS, Canadian Car-
diovascular Society; NO, nitric oxide; HSCRP, high sensi-
tive C-reactive protein.
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SF-36 and its eight subscales, NO level, ET1 level, and 
HSCRP level, there was no statistical significance be-
tween both groups (Table 6).
DISCUSSION
This randomized clinical trial-pilot study demonstrates 
for the first time effects of EECP on inflammatory param-
eters of NO, ET1, and HSCRP and QoL in patients with 
CAD. We hypothesized that 20 sessions EECP treatment 
could improve inflammatory parameters of CAD patients.
The present study showed that 20 sessions of EECP did 
not significantly improve the QoL, NO, ET1, and HSCRP 
level. 
As an effective noninvasive treatment method for pa-
tients with CAD, EECP has been proven to exert various 
beneficial effects on the cardiovascular system, such as 
increasing the coronary perfusion pressure and arterial 
wall shear stress [10,11]. 
Benefits associated with EECP include the reduction of 
angina and nitrate use, an increased exercise tolerance, 
favorable psychosocial effects and an enhanced QoL as 








   Total score 64.9±3.2 65.4±3.5 0.54
   Subscales - -
Physical function 71.9±4.5 71.6±4.4 0.83
Physical health 58.5±8.3 58.9±7.9 1.00
Emotional problem 63.1±8.6 64.3±7.5 1.00
Energy 56.6±5.1 57.8±5.6 0.66
Well being 65.8±4.3 68.4±4.2 0.09
Social function 67.5±4.1 66.2±3.9 0.69
Pain 72.1±4.7 73.8±5.0 0.54
General health 63.9±3.5 61.9±3.3 0.38
NO level 7.87±0.99 8.21±1.27 0.63
Endothelin 1 level 7.49±2.81 5.22±0.60 0.43
HSCRP level 1.52±0.7 1.27±0.4 0.33
Values are presented as mean±standard deviation.
EECP, enhanced external counterpulsation; QoL, quality 
of life; NO, nitric oxide; HSCRP, high sensitive C-reactive 
protein.








   Total score 66.0±3.7 69.8±3.5 0.23
   Subscales
Physical function 73.0±20.4 76.7±4.5 0.17
Physical health 62.5±8.0 63.7±8.9 0.89
Emotional problem 64.9±9.8 75.5±34.0 0.39
Energy 61.0±4.1 61.7±4.2 0.81
Well being 65.4±3.0 65.0±3.6 0.90
Social function 76.8±4.1 77.7±4.4 0.85
Pain 65±30.5 71±6.4 0.28
General health 60.2±4.6 66.4±4.1 0.09
NO level 8.28±6.49 8.31±6.26 0.87
Endothelin 1 level 4.58±5.11 4.34±3.63 0.66
HSCRP level 1.98±0.6 1.75±0.6 0.27
Values are presented as mean±standard deviation.
CR, cardiac rehabilitation; QoL, quality of life; NO, nitric 
oxide; HSCRP, high sensitive C-reactive protein.
Table 6. Comparison of EECP and CR group in the im-










   Total score 0.5±3.9 3.8±3.6 0.31
   Subscales - -
Physical function -0.3±1.3 3.7±1.9 0.18
Physical health 0.4±4.2 1.2±4.7 0.90
Emotional problem 1.2±1.1 10.6±14.8 0.40
Energy 1.2±1.6 0.7±14.3 0.92
Well being 2.6±6.4 -0.4±4.9 0.42
Social function -1.3±3.9 0.9±2.6 0.70
Pain 1.7±1.6 6.2±2.4 0.47
General health -2.0±9.9 6.2±15.9 0.32
NO level 0.34±0.03 0.03±0.82 0.67
Endothelin 1 level 2.27±12.6 0.24±2.3 0.48
HSCRP level 0.25±1.1 0.23±0.9 0.93
Values are presented as mean±standard deviation.
EECP, enhanced external counterpulsation; CR, car-
diac rehabilitation; QoL, quality of life; NO, nitric oxide; 
HSCRP, high sensitive C-reactive protein.
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well as a prolongation of the time to exercise-induced ST-
segment depression and an accompanying resolution of 
myocardial perfusion defects [12]. 
The mechanisms of EECP responsible for improving the 
coronary blood flow are unclear. Numerous studies have 
identified several possible mechanisms of action of EECP. 
Initially, the prevailing theory was that EECP increases 
the coronary collateral circulation [13].
The safety of EECP treatment was demonstrated with 
minor adverse effects, such as skin blebs in patients with 
left ventricular dysfunction [4]. 
In different conditions and diseases showed EECP 
promising results. A prospective evaluation on the EECP 
in congestive heart failure showed an improved exercise 
tolerance and QoL due to EECP treatment [14]. Liu et 
al. [15] demonstrated that, even though the mean blood 
pressure did not significantly change, EECP treatment is 
associated with a significant elevation in the right com-
mon carotid artery blood flow.  Lin et al. [16] reported 
that EECP was able to improve the mean blood pressure 
and cerebral perfusion in patients after ischemic stroke. 
Another study concluded that angina patients with aortic 
stenosis who underwent EECP had clinically important 
symptomatic and hemodynamic improvements compa-
rable to their non-aortic stenosis counterparts [17]. Ru-
angkanchanasetr et al. [4] even demonstrated that EECP 
could improve the long-term renal function in cardiac 
patients especially in cases with declined renal function. 
Previous studies have shown that elevated inflamma-
tory biomarkers are predictive of future peripheral arte-
rial diseases, CAD and cerebrovascular accidents and any 
improvement in these markers could halt CAD progres-
sion [6,18,19]. HSCRP increased in baseline samples of 
subjects who subsequently developed peripheral arte-
rial disease compared with controls and the calculated 
relative risks for CAD increased significantly with each 
increasing quartile of measured HSCRP [8].
Therapeutic lifestyle changes affected through a three-
month cardiac rehabilitation program significantly im-
proved numerous cardiac risk factors. With this approach 
to a secondary prevention, Milani et al. [5] observed sig-
nificant reductions in HSCRP levels. These findings iden-
tify another clinical modality of reducing HSCRP beyond 
use of statin drugs and suggest an additional benefit of 
formal phase II cardiac rehabilitation and exercise train-
ing programs.
 Comparing in our study, the absence of a significant 
improvement shows that 20 sessions EECP is not effec-
tive. However, we would not come to the conclusion to 
rule out EECP effects on CAD patients. Our study shows a 
non-significant improvement of inflammatory biomark-
ers from baseline values and this could be an indication 
of possible significant results in case of continuing EECP 
beyond twenty sessions. 
Also, in the conventional CR group we did not find a 
significant improvement of inflammatory biomarkers. 
Based on the pilot nature of our study, these finding 
could be explained with different hypothesizes; first, we 
would hypothesize that inflammatory biomarkers are not 
sensitive outcome measures for the cardiac rehabilitation 
assessment and that they could not rule in or rule out 
any cardiac rehabilitation method. Second, our study is a 
pilot study and our sample size could be too small. Third, 
there is not definitive and worldwide accepted protocol 
for CR sessions and these results could simply indicate 
that this protocol has no effect on inflammatory biomark-
ers of CAD patients. We need focused studies on these 
subjects for a definite conclusion on this matter.
Heffernan et al. [20] investigated the effect of resistance 
training on systemic inflammatory biomarkers such as 
CRP in African-Americans compared with White men. 
They found different responses between these two ethnic 
groups which could suggest the importance of ethnicity 
in the response of inflammatory biomarkers to exercise 
training.
Whether racial differences are truly biological or merely 
reflect differences in environmental factors (i.e., diet, so-
cial support) and/or psychosocial factors (i.e., perceived 
stress, discrimination, coping ability, and locus of con-
trol) is beyond the scope of this study.
We did not include psychological and dietary man-
agement in our interventions and this could be another 
influencing factor. Also subject’s stress levels were not 
controlled during this study what may have influenced 
overall findings.
There are different factors effecting conventional CR 
results like choice of outcome measures for improvement 
evaluation, age, sex, BMI, time of biochemical blood 
sampling after CR, sample size and ethnicity of subject 
group.
Taking all trials together, it may be speculated that a 
training period of only 7 weeks, as preferred in our study, 
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may not be long enough to induce changes in inflamma-
tory biomarkers, since most studies were carried out for 
12 to 26 weeks. These results do not exclude beneficial 
effects of conventional CR or EECP in CAD patients, but it 
undermines effects of 7-week conventional CR and EECP 
program on biochemical markers in CAD patients.
It should be highlighted that our non-significant im-
provement results in both groups are not implying an in-
effectiveness of EECP or conventional CR in 20 sessions. 
This study only shows that we should not expect signifi-
cant change in biochemical markers with 20 sessions of 
EECP or conventional CR. Also we should mention that 
our results imply to the ethnicity of Azeri people with 
their regional diet and living in a higher altitude from sea 
level.
Our pilot study included twenty sessions of EECP and 
CR. The main limitations of our study are the small num-
bers of rehabilitation sessions and the small sample size. 
Based on mild but not significant improvements, more 
sessions might show significant results. So, further stud-
ies should be conducted with more sessions of EECP and 
larger groups of study subjects. 
In conclusion, twenty sessions of EECP treatment had 
no significant effect on the improvement of QoL, NO, 
ET1, and HSCRP in CAD patients. Further studies are 
necessary with more sessions of EECP and a larger sam-
ple size with controls. 
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